This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert A. O'Reilly, MD

Arch Intern Med. 1981;141(4):458-459.

Abstract
• Because daily ingestion of 592 mL of table wine (12% ethanol by volume) during mealtime had no notable effect on long-term, "therapeutic" hypoprothrombinemia with racemic warfarin sodium in normal subjects, similar experiments were repeated using fortified wine (20% ethanol by volume) during fasting. For 21 days, seven normal subjects were given therapeutic levels of the anticoagulant racemic warfarin alone and with warfarin plus 296 mL/day of fortified wine during fasting. The blood-alcohol level of 296 mL of fortified wine ingested during fasting is equivalent to 1,646 mL of table wine ingested during mealtime. No significant difference occurred in the onestage prothrombin activity or the plasma levels of warfarin in any subject. It is concluded that daily ingestion of fortified wine during fasting has no effect on therapeutic levels of hypoprothrombinemia of normal humans.

(Arch Intern Med 1981;141:458-459)

Author Affiliations
From the Departments of Medicine, Santa Clara Valley Medical Center, San Jose, Calif; University of California School of Medicine, San Francisco; and Hematology Research Laboratory, Institute for Medical Research of Santa Clara County, San Jose.

Footnotes
Accepted for publication March 17, 1980.

Reprint requests to Department of Medicine, Santa Clara Valley Medical Center, 751 S Bascom Ave, San Jose, CA 95128 (Dr O'Reilly).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Ansell et al.
Chest 2008;133:160S-198S.
ABSTRACT | FULL TEXT  

Systematic Overview of Warfarin and Its Drug and Food Interactions
Holbrook et al.
Arch Intern Med 2005;165:1095-1106.
ABSTRACT | FULL TEXT  

The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Ansell et al.
Chest 2004;126:204S-233S.
ABSTRACT | FULL TEXT  

The Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor, Are Unaffected by a Single Dose of Alcohol
Sarich et al.
J Clin Pharmacol 2004;44:388-393.
ABSTRACT | FULL TEXT  

American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
Hirsh et al.
J Am Coll Cardiol 2003;41:1633-1652.
FULL TEXT  

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
Hirsh et al.
Circulation 2003;107:1692-1711.
FULL TEXT  

Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh et al.
Chest 2001;119 :8S-21S.
FULL TEXT  

Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation
Hylek et al.
JAMA 1998;279:657-662.
ABSTRACT | FULL TEXT  

Anticoagulation: Practice Focus in an Ambulatory Clinic
Engle
Journal of Pharmacy Practice 1990;3:349-357.
ABSTRACT